Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Medtronic
McKinsey
Moodys
Farmers Insurance
Fuji
Mallinckrodt
Teva
Boehringer Ingelheim

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,528,086

« Back to Dashboard

Which drugs does patent 6,528,086 protect, and when does it expire?

Patent 6,528,086 protects PLIAGLIS and is included in one NDA.

This patent has fifteen patent family members in eleven countries.
Summary for Patent: 6,528,086
Title: Methods and apparatus for drug delivery involving phase changing formulations
Abstract:This invention relates to an apparatus and method of drug delivery on a human body surface. The formulation comprises a drug, a conversion agent capable of converting the formulation from a less solid phase to a coherent, soft, solid phase, and a vehicle medium or carrier for the drug and conversion agent. The drug formulation is applied to this human body surface in its less than solid phase and is subsequently converted to a soft solid phase while the drug is being delivered through the human body surface. After delivery of the drug is complete, the soft solid formulation can be removed or peeled from the body surface as a coherent solid formulation. The drug formulation provides control over drug delivery rates and allows the formulation to be removed without leaving a messy, residual formulation on the body surface.
Inventor(s): Zhang; Jie (Salt Lake City, UT)
Assignee: Zars, Inc. (Salt Lake City, UT)
Application Number:09/407,720
Patent Claim Types:
see list of patent claims
Use; Formulation; Delivery;

Drugs Protected by US Patent 6,528,086

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Taro Pharms PLIAGLIS lidocaine; tetracaine CREAM;TOPICAL 021717-001 Jun 29, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,528,086

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 1376043 ➤ Try a Free Trial
China 100367927 ➤ Try a Free Trial
China 101219108 ➤ Try a Free Trial
Germany 60032021 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
McKinsey
Teva
Baxter
Federal Trade Commission
Queensland Health
Cipla
Cerilliant
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.